Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieDrug RepositioningHistone Deacetylase InhibitorsHumansSurface Plasmon ResonanceHistone Deacetylases
Modelling-filtered drug repurposing and first-in-protein SPR validation of histone deacetylase 4 inhibitors for Ataxia-telangiectasia.
Alessia Distefano, Matteo Pappalardo, Roberta Turco, Giuseppe Grasso, Salvatore Guccione
Published: 202510.1016/j.biopha.2025.118621
Abstract
Ataxia-telangiectasia is a neurodegenerative disorder characterised by ATM deficiency and aberrant nuclear accumulation of Histone deacetylase 4 (HDAC4) in Purkinje neurons. Targeting HDAC4 has thus emerged as a promising therapeutic strategy. Here,…
Preview only. Read the full abstract at the source